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ABSTRACT
Background. This study aimed to evaluate the role of
surgery for patients with high-grade pancreatic neuroen-
docrine carcinoma (hgPNEC) in a large Nordic multicenter
cohort study. Prior studies evaluating the role of surgery for
patients with hgPNEC are limited, and the benefit of the
surgery is uncertain.
Methods. Data from patients with a diagnosis of hgPNEC
determined between 1998 and 2012 were retrospectively
registered at 10 Nordic university hospitals. Kaplan–Meier
curves were used to compare the overall survival of dif-
ferent treatment groups, and Cox-regression analysis was
used to evaluate factors potentially influencing survival.
Results. The study registered 119 patients. The median
survival period from the time of metastasis was 23 months
for patients undergoing initial resection of localized non-
metastatic disease and chemotherapy at the time of
recurrence (n = 14), 29 months for patients undergoing
resection of the primary tumor and resection/radiofre-
quency ablation of synchronous metastatic liver disease
(n = 12), and 13 months for patients with synchronous
metastatic disease given systemic chemotherapy alone
(n = 78). The 3-year survival rate after surgery of the
primary tumor and metastatic disease was 69 %. Resection
of the primary tumor was an independent factor for
improved survival after occurrence of metastatic disease.
Conclusions. Patients with resected localized non-
metastatic hgPNEC and later metastatic disease seemed to
benefit from initial resection of the primary tumor. Patients
selected for resection of the primary tumor and syn-
chronous liver metastases had a high 3-year survival rate.
Selected patients with both localized hgPNEC and meta-
static hgPNEC should be considered for radical surgical
treatment.
High-grade gastroenteropancreatic neuroendocrine car-
cinomas (NECs) are rare but increasing in incidence,1,2
accounting for 10 to 20 % of all malignant gastroen-
teropancreatic neuroendocrine neoplasms (NENs).3 A NEC
is defined as an NEN with a Ki67 proliferation index
[20 %.4,5 High-grade pancreatic neuroendocrine carcino-
mas (hgPNECs) are highly malignant neoplasms that
typically invade adjacent structures or have metastasized at
diagnosis.6 The median survival time for patients with
advanced hgPNEC varies from 11 to 21 months.1,7,8
The largest cohort of patients with advanced gastroen-
teropancreatic NECs to date was recently published.1 In
this Nordic multicenter study that included 305 patients, 71
had an hgPNEC, and 15 % (n = 11) of these patients had a
resection of the primary tumor. In another recent report, the
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outcomes of surgery for 310 patients with pancreatic
NENs, including 24 patients with hgPNEC, were pre-
sented.9 However, the role of surgery for hgPNEC was not
assessed further in either of these studies.
Although surgical treatment of hgPNEC is controversial
because most patients experience recurrent disease, reports
discuss a beneficial effect of surgical treatment on sur-
vival.10–14 These studies are either small case reports/series or
larger series with lack of a well-defined comparative group.
The current consensus guidelines of the European Neu-
roendocrine Tumor Society (ENETS) for the surgical
treatment of hgPNEC refer to only two studies,15,16 and state
that ‘‘curative surgery should be attempted in localized
disease’’ and that ‘‘debulking and surgery for liver metas-
tases are not recommended‘‘.17 The consensus guidelines of
the North American Neuroendocrine Tumor Society
(NANETS) state that ‘‘the benefit of surgery among patients
who have completed a course of chemoradiation is uncer-
tain,’’ with no references to studies on pancreatic
surgery.18,19 Surgery is not even mentioned in the section on
treatment for metastatic hgPNEC. Moreover, the European
Society for Medical Oncology’s (ESMO) guidelines state
that ‘‘it is a general agreement not to operate on G3 pan-
creatic NEC.’’ 20 This underscores the importance of
defining the role of surgery for patients with hgPNEC.11
Because no clear evidence for the role of surgery used to
treat hgPNEC exists, this study aimed to investigate the
effect of surgery on the survival in patients with metastatic
hgPNEC, and to identify potential prognostic factors for
the survival in these patients. We investigated this in a
retrospective study of data from a Nordic NEC registry.
METHODS
In this multicenter retrospective study, patients were
identified from neuroendocrine registries, surgical records,
chemotherapy registries, coding in hospital charts, and
pathology coding at ten Nordic university hospitals. The 71
patients included in this study have been described previ-
ously in reports on another study with a different aim.1
The participating centers provided data as specified
through standardized case report forms. An inclusion cri-
terion was a histopathologically confirmed diagnosis of
hgPNEC, defined as neuroendocrine tissue with a Ki67
value greater than 20 % in the primary tumor or metastasis
pre- or intraoperatively, between August 1998 and October
2012. Histopathologic data were evaluated according to the
World Health Organization (WHO) 2010 classification for
NENs of the gastroenteropancreatic system4 and the
ENETS TNM classification.21 In addition, resection status,
tumor location, and tumor diameter were recorded.
Tumor morphology was based on pathology reports and
classified into small cell or non-small cell morphology. Non-
small cell morphology was defined as the presence of large-
cell morphology or no mentioning of small-cell morphology
in the pathology report. All Ki67 values reported for the
subgroups that underwent surgery were from the primary
tumor. For the patients not treated by surgery, the Ki67 values
were not consistently from the primary tumor. The highest
recorded value was used independently of organ. We chose to
use a cutoff of 55 % for the Ki67 index because this cutoff
value has previously been shown to distinguish two separate
groups of gastroenteropancreatic NEC in terms of survival
and response to chemotherapy.1,22
Performance status (PS) was defined according to the
Eastern Cooperative Oncology Group (ECOG) definition 23
and registered at the time of the metastatic disease diag-
nosis. Reasons for exclusion from a surgical program
included severe grade of comorbidity, preoperative find-
ings of unresectable disease, and metastatic disease with
aggressive tumor growth during the follow-up period.
Surgery of metastasis was defined as surgical resection,
liver transplantation, and/or radiofrequency ablation (RFA)
of liver metastases. The ethics committees in Norway,
Sweden, Denmark, and Finland approved the study.
Follow-up time and overall survival were defined as the
time from metastasis until death or last observation to
minimize bias when the oncologic treatment of patients
with synchronous metastatic disease was compared with
the treatment of patients with metachronous metastatic
disease. For the best supportive care (BSC) group, these
parameters were defined from the time of diagnosis until
death because these patients did not receive any active
treatment. The survival times were censored at the end of
the study (26 September 2013).
Statistical Analysis
Descriptive statistics are presented as frequencies,
medians, ranges, and proportions. Overall survival was
constructed using Kaplan–Meier curves with accompany-
ing risk tables. Cox-proportional hazard models (uni- and
multivariate) were fitted for evaluation of the effect of
factors potentially influencing survival.
Due to the limited number of patients included in this
study, we constructed a model with no more than six
variables. After each of these variables had been subjected
to an a priori evaluation to determine its clinical relevance,
the following five variables, presumably independent, were
included in the Cox-analysis: resection of primary tumor,
courses of chemotherapy, Ki67, small cell morphology,
and PS. The independence of the included variables was
confirmed before performance of the Cox analysis. The
assumption of proportional hazards was verified graphi-
cally and checked using tests of proportional hazard
assumption. Cox-regression analysis was calculated based
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on 3- and 5-year follow-up data. All p values lower than
0.05 were regarded as statistically significant. Data analy-
sis was performed with the statistical software Stata
(Version 13.1, StataCorp, College Station, Texas, USA).24
RESULTS
Patient Characteristics
The study enrolled 119 patients with a median age of
60 years (range 23–85 years). At the initial diagnosis,
85 % of the patients (n = 101) had metastatic disease. The
main patient characteristics are presented in Table 1. The
patients were divided into treatment groups as illustrated
by the flowchart in Fig. 1.
Surgery
Of 28 patients (24 %) who underwent surgical treatment,
13 had a preoperative diagnosis of hgPNEC based on
biopsy. For 14 patients, resection of the primary tumor in
nonmetastatic disease (SURG1) was performed. All these
patients experienced recurrent disease, as a local recurrence
only (n = 1), as metastases only (n = 12), or both (n = 1).
The median time to recurrence or metastasis in this group
was 7 months (range 2–14 months) from the time of initial
surgery. Resection of the primary tumor and metastatic liver
disease was performed for 12 patients as single- or multiple-
stage surgery (SURG2). Two patients underwent resection
of only the primary tumor in metastatic disease due to liver
metastases diagnosed intraoperatively (SURG3).
Of the 12 patients (SURG2) who underwent resection of
metastatic disease, eight underwent liver resection (seven
concomitant resections only and one later resection only)
and four underwent RFA of liver metastasis (three con-
comitant resections only and one later RFA only). One
patient underwent liver resection and later liver transplan-
tation. One patient underwent concomitant adrenalectomy
and nephrectomy and later liver resection, and one patient
underwent concomitant resection of the liver, pleura, and
pericardium.
Altogether, 26 patients underwent surgery with curative
intent. For two of these patients, liver metastases were
diagnosed intraoperatively. The one patient, who under-
went palliative surgery, had a malignant insulinoma and
underwent resection of the primary tumor and debulking of
metastatic disease in the liver and retroperitoneum. The
other patient underwent resection of the primary tumor and
debulking of liver metastases while experiencing
stable disease with administration of systemic chemother-
apy. One patient died 13 days after surgery due to
multiorgan failure after intraoperative bleeding from the
hepatic artery and the superior mesenteric artery. The
clinicopathologic characteristics of the 28 patients who
underwent surgery are presented in Table 2.
Chemotherapy
All but one patient who underwent surgical treatment
also received chemotherapy. Chemotherapy alone was
administered to 82 patients (69 %). Of these 82 patients, 4
had nonmetastatic disease (CT1) and 78 had metastatic
disease (CT2). Among all the patients who received
chemotherapy, 54 received one to four courses and 52
received more than four courses. The following
chemotherapy regimens were administered: cisplatin/eto-
poside (n = 50), carboplatin/etoposide (n = 26),
carboplatin/etoposide/vincristine (n = 11), and a combi-
nation of cisplatin/etoposide and carboplatin/etoposide
(n = 2). The remaining patients were initially treated with
other regimens based on the assumption of pancreatic
ductal adenocarcinoma. Patient data on the number of
chemotherapy courses were missing for three patients.
Survival
Follow-up information was available for all the patients.
The SURG1 group included two patients who experienced
local recurrence after resection of the primary tumor before
or at the same time as their diagnosis of liver metastasis.
These two patients were excluded from the survival anal-
ysis. During the follow-up period, 92 patients (77 %) died
of disease. The median follow-up period was 13 months
(range 0–165 months).
The disease-free survival time was 7 months for the
SURG1 group and 18 months for the SURG2 group. The
median survival time after diagnosis of metastatic disease
for all the patients who received surgical treatment,
chemotherapy, or both was 15 months. The median sur-
vival time was longer in the surgical groups (SURG1–
SURG3) (23 months) than in the nonsurgical groups (CT1–
CT2) (13 months) (Table 1). The median survival time for
the patients receiving BSC was 2 months, and all died
during the follow-up period. The 3-year survival rates were
45 % for SURG1, 69 % for SURG2, and 17 % for CT2
(Fig. 2). The patients undergoing combined surgical treat-
ment and chemotherapy had significantly better survival
times than the patients receiving chemotherapy alone
(SURG 1 and SURG 2 vs CT2: p = 0.001).
We also compared the effect of Ki67 on survival for the
surgically resected patients but did not find any statistically
significant difference between the patients with a Ki67
value lower than 55 % and those with a Ki67 value of
55 % or higher (p = 0.92). The multivariate Cox-regres-
sion analysis showed that resection of the primary tumor,
more than four courses of chemotherapy, a Ki67 value
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lower than 55 %, and a PS of 0 were statistically significant
independent factors for improved survival, with no differ-
ence between the 3- and 5-year follow-up data (Table 3).
DISCUSSION
This study investigated the effect of surgery on patients
with hgPNEC and demonstrated that resection of the
primary tumor was an independent prognostic factor of
improved survival for patients with hgPNEC at different
disease stages. This may suggest that resection of the pri-
mary tumor in localized hgPNEC should be considered,
and additionally, that patients with resectable hgPNEC and
resectable synchronous metastatic disease should be con-
sidered for surgery of both the primary tumor and the
metastases. Surgical resection is an established treatment
Localized non-
metastatic  
n=18
Metastatic
n=101
PNEC
n=119
Chemotherapy
1-4 courses, n=5
>4 courses,  n=9
Chemotherapy
1-4 courses, n=1
>4 courses,  n=3
CT 1
n=4
Chemotherapy
1-4 courses, n=43
>4 courses,  n=34
CT 2
n=78
Surgery of 
primary
tumor
SURG 1
n=14
Surgery of 
primary tumor 
and liver 
metastasis
SURG 2
n=12
Chemotherapy
1-4 courses, n=4
>4 courses,  n=6
Surgery of 
primary 
tumor
SURG 3
n=2
Chemotherapy
1-4 courses, n=1
>4 courses,  n=0
Best 
supportive 
care
BSC
n=9
FIG. 1 Flowchart of the patients and treatment groups in the study. Patient data on the number of chemotherapy courses were missing for three
patients
TABLE 2 Clinicopathologic characteristics of 28 patients with pancreatic neuroendocrine carcinoma who underwent surgical treatment
SURG1 SURG2 SURG3
No. of patients 14 12 2
Primary location 12 Head, 1 tail, 1 whole organ 6 Head, 4 tail, 2 whole organ 2 Head
Synchronous metastasis
location
NA 12 Liver, 1 gallbladder, 1 adrenal gland,
1 kidney, 1 thoracic lymph nodes
2 Liver
Curative intent of surgery 14 Yes 10 Yes, 2 no (1 with malignant insulinoma,
1 with stable disease on systemic
chemotherapy)
2 Yes (both with intraoperative
detection of liver metastasis)
Median tumor size: cm (range) 3.0 (0.8–8.0) 5.0 (1.5–17.0) 8.0 (5.0–11.0)
Staging (ENETS) T 1 T1, 3 T2, 9 T3, 1 T4 1 T1, 3 T2, 3 T3, 4 T4, 1 Tx 1 T3, 1 T4
Median Ki67: % (range)
Primary 60 (20–90) 37 (5–100) 90 (80–100)
Metastasis NA 50 (25–100) NA
Surgery primary tumor 12 W, 1 DP, 1 TP 6 W, 4 DP, 2 T 2 W
Surgery metastasis NA 8 Liver resections, 4 RFAs, 1 LTX,
1 adrenalectomy/nephrectomy,
1 pleurectomy/pericardectomy
NA
SURG1 surgery of primary tumor in nonmetastatic disease, SURG2 surgery of primary tumor and metastatic liver disease, SURG3 surgery of
primary tumor only in metastatic disease, NA not applicable, W Whipple’s procedure, DP distal pancreatectomy, TP total pancreatectomy, RFA
radiofrequency ablation, LTX liver transplantation
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method for pancreatic ductal adenocarcinoma25 as well as
for low- and intermediate-grade pancreatic neuroendocrine
tumors,9 but the role of surgery in the treatment of hgPNEC
is uncertain due to the lack of data from large comparative
cohorts of patients with hgPNEC.
Surgery for metastatic disease in patients with hgPNEC
is not recommended in the current ENETS and NANETS
guidelines.17–19 However, the current study demonstrated
that surgery of localized nonmetastatic disease combined
with chemotherapy improved survival despite recurrent
disease after a median time of 7 months postoperatively
compared with chemotherapy alone. The early manifesta-
tion of metastatic disease in 13 of 14 patients with localized
disease at the time of initial surgery may indicate that these
patients likely had occult metastases at the time of resec-
tion. Accordingly, it remains to be established whether
chemotherapy also should be given in a neoadjuvant setting.
Interestingly, the subgroup of patients who underwent sur-
gery of the primary tumor and synchronous metastatic
disease had the longest median survival (29 months).
Our results, especially the 3-year survival rate of 69 %
for patients with resection of all metastatic disease
(SURG2), question the very rigid guideline recommenda-
tions.17–19 Our data showed a surprisingly good survival
among patients with synchronous disease who underwent
resection. We were not able to identify any bias or obvious
explanations for the favorable survival of this group of
patients. However, recent data have shown considerable
heterogeneity within the G3 NEC group,5 probably much
more than for patients with other gastrointestinal malig-
nancies, and this might explain why they seem to behave
differently as a group. Based on the results of our study, we
suggest that hgPNEC patients should be considered on an
individual basis for surgery combined with chemotherapy
if all tumor tissue can potentially be resected.
Another important finding was that resection of the pri-
mary tumor seemed to result in better survival from the date
of metastatic disease for the patients with metachronous
metastatic disease than for the patients with synchronous
metastatic disease who did not undergo resection of the
primary tumor. One obvious explanation for this may be
that having metachronous metastatic disease is prognosti-
cally better than having synchronous disease. However,
comparison of the independent prognostic factors found in
the Nordic NEC study1 (PS, lactate dehydrogenase levels,
and platelets) showed no major differences in these patient
characteristics. The Ki67 index was more often lower than
55 % for the patients with synchronous disease (68 %) than
for the patients with metachronous disease (50 %), which
may underscore the importance of surgical treatment
regardless of the Ki67 value. This is supported by another
important finding in our study, which showed similar sur-
vival for the surgically resected patients with a Ki67 lower
than 55 % and those with a Ki67 of 55 % or higher. This
indicates that patients with hgPNEC should be considered
for surgery, even those whose Ki67 values are high.
A recent study that included only poorly differentiated
colorectal NEC did not demonstrate any benefit from
resection of the primary tumor.26 However, primary colonic
NEC has a worse prognosis than hgPNEC.27 Our observa-
tion of 23 months survival after surgical resection is better
than the 12 months survival observed in a cohort of 44
patients with poorly differentiated hgPNEC reported by
Basturk et al.8 Tumor location, surgical procedure, tumor
size, and T stage were comparable between these studies.
However, the study by Basturk et al. 8 included only poorly
differentiated hgPNEC, whereas our study included all
hgPNEC cases with a Ki67 higher than 20 % without dif-
ferentiation of grading. The optimal histologic classification
of NEN G3 (Ki67[ 20 %) remains controversial,5 and
well-differentiated tumors have been found among tumors
with a Ki67 higher than 20 %.28 Patients with well-differ-
entiated hgPNEC seem to have a longer survival than
patients with poorly differentiated hgPNEC,29,30 which may
bias comparison between these studies.
Small and large cell morphology has previously been
evaluated as a prognostic factor for patients with gas-
troenteropancreatic NECs. Results have been divergent,
Kaplan-Meier survival estimates
Times since metastasis (months)
Number at risk
SURG1 11 59 3 3
610 3 3
2143 9 4
00 0 0
0
2
3
0
SURG2 11
CT2 76
BSC 9
SURG1 SURG2 
CT2 BSC 
0
0.
00
0.
25
0.
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0.
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1.
00
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al
 (
pr
op
or
tio
ns
)
FIG. 2 Kaplan–Meier survival curves for patients with pancreatic
neuroendocrine carcinoma according to treatment. SURG1, surgery of
primary tumor in nonmetastatic disease; SURG2, surgery of primary
tumor and metastatic liver disease; CT2, chemotherapy only for
metastatic disease; BSC, best supportive care. Log-rank test: SURG2
vs CT2 after 3 years (p\ 0.01)/5 years (p\ 0.01); SURG1 vs CT2
after 3 years (p = 0.08)/5 years (p = 0.09). SURG1 and SURG 2 vs
CT2 after 3 years (p = 0.001)/5 years (p = 0.001). Six patients were
excluded from the survival analysis due to local recurrence after
surgery (SURG1, n = 2) or unknown time of metastasis (SURG1,
n = 1; SURG2, n = 1; CT2, n = 2)
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with improved survival related to large cell morphology
reported by some27 and no difference in survival reported
by others.1,8,26 In our study, small cell morphology was not
a statistically significant prognostic factor. Thus, the clin-
ical relevance of this morphologic classification remains
uncertain for hgPNEC patients. Patients with poor PS
received BSC without chemotherapy, which was related to
a poor oncologic outcome, with a median survival time of
only 2 months, similar to other reports.10
Patients with metastatic hgPNEC are traditionally trea-
ted with palliative chemotherapy.17,18 In our study, all but
one patient who underwent surgical treatment were given
adjuvant chemotherapy. Recent NANETS guidelines rec-
ommend adjuvant platinum-based chemotherapy after
radical surgery, although there are no studies to support
such a recommendation.18 The same is the case for the
duration of chemotherapy. The multivariate analysis
showed that more than four courses of administered adju-
vant chemotherapy is a significant factor of improved
survival compared with one to four courses. Our study may
suggest that more than four courses are better than one to
four courses as postoperative chemotherapy, although there
will be a bias concerning which patients are given or can
receive more than four courses.
A clear limitation of our study was the small sample
size, especially for the patients who underwent surgical
treatment. A further limitation of the study was its retro-
spective design, with the risk of unintended bias. The dates
of diagnosis and treatment early in the cohort versus late in
the cohort were not tested for influence on the results, and
we did not take into account that patients may have dif-
ferent comorbidities, thus resulting in a nonregistered
selection bias. Because the data were acquired from several
institutions in different countries, there may have been a
selection bias associated with divergent diagnostic and
treatment strategies among the participating institutions. In
addition, because the patients included in this study had
their diagnoses determined during a period of 14 years, the
diagnostic procedures likely developed over time.
Another weakness of our study was the lack of a cen-
tralized pathologic reevaluation of the tissues from the
enrolled patients. The lack of Ki67 values from both pri-
mary tumor and metastatic tissue was another limitation of
the study. For seven patients, all of whom underwent sur-
gery, Ki67 was determined from both the primary and
metastatic tissue. Metastatic tissue generally had a higher
Ki67 than primary tumor tissue, consistent with other
reports.31,32 However, in the studied cohort, the mean Ki67
value for those who did not undergo surgery was
48 ± 26 %, whereas the mean Ki67 value of the metastatic
tissue from the surgically treated patients was 47 ± 26 %.
Based on these data, the two groups seemed comparable in
terms of tumor biology defined by Ki67. Other limitations
of the study included absence of data on the total hepatic
tumor burden for patients with liver metastases as well as
heterogeneity of the chemotherapy regimens administered.
The data from this study indicate that surgical treatment
combined with chemotherapy may improve the survival of
patients with metastatic hgPNEC compared with chemother-
apy alone. Resection of the primary tumor is an independent
prognostic factor of improved survival for patients with
metastatic hgPNEC and should therefore always be consid-
ered. Furthermore, patients with resectable hgPNEC and
resectable synchronous metastatic disease should be consid-
ered for surgery of both the primary tumor and the metastases.
Our study suggests the notion of surgery as a principle for the
treatment of patients with hgPNEC.
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